Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Open accessThe DOI matches its Crossref record; 120 of the 124 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD), once considered a rare disease, is now the most common form of dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate antagonists) are safe but of limited benefit to most patients, offering symptomatic relief without successful cure of the disease. Since the last several decades, there has been a great need for the development of a treatment that might cure the underlying causes of AD and thereby slow its progression in vulnerable individuals. That is why phase I, II, and III studies that act on several fronts, such as cognitive improvement, symptom reduction, and enhancing the basic biology of AD, are imperative to stop the disease. This review discusses current treatment strategies, summarizing the clinical features and pharmacological properties, along with molecular docking analyses of the existing medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It modulates glutamate transmission and dopamine receptors, exhibiting certain efficacy in improving patients’ cognitive function, daily living abilities, and behavior.409,410”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [409]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These drugs primarily function by modulating neurotransmitter levels but cannot alter the course of the disease,409,411 which are instructive for designing new drugs.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [409]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828 · cited 2×
“4 [8], and the data were interpreted using Discovery Studio [9] and UCSF Chimera [10].”
MethodInfluentialTrott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 1×
“4 [8], and the data were interpreted using Discovery Studio [9] and UCSF Chimera [10].”
MethodAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 2×
“Tau is a protein believed to play a significant role in the progression of AD; researchers are experimenting with several methods to target tau with the goal of altering the course of the disease [84].”
BackgroundResultAcetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · cited 1×
“Inflammation has now been observed in numerous investigations using postmortem tissues from samples of AD patients, but the role of inflammation in AD is not yet fully understood [91,92].”
BackgroundKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“The amyloid cascade hypothesis is one of the signaling pathways that has been thoroughly investigated concerning AD [81].”
BackgroundAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Glutamate as a neurotransmitter in the healthy brain
Zhou, Y., & Danbolt, N. C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1180-8 · Cited by 979 · cited 1×
“Glutamate transmission modulation–glutamate is the most abundant excitatory neurotransmitter in the central nervous system, with about 40% of synapses containing it [67].”
BackgroundGlutamate receptor function in learning and memory
Riedel, G. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00272-3 · Cited by 962 · cited 1×
“Numerous preclinical studies have shown that when glutamate synapses are blocked, no new memories can form [68].”
BackgroundMicroglial Activation and its Implications in the Brain Diseases
Thameem Dheen, S., Kaur, C., & Ling, E.-A. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780597961 · Cited by 952 · cited 1×
“These molecules cause damage to neurons, leading to the development of cognitive symptoms [93].”
BackgroundPhysiology of the Autonomic Nervous System
McCorry, L. K. (2007) · American Journal of Pharmaceutical Education · doi:10.5688/aj710478 · Cited by 888 · cited 1×
“Besides the central nervous system, ACh is also found in the parasympathetic vegetative nervous system [14], slows the heart rate, and stimulates the gastrointestinal tract and bladder.”
BackgroundThe secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Alzheimer’s disease drug development pipeline: 2024
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12465 · Cited by 702
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · cited 1×
“Despite these advancements, only a few medications for AD have been licensed, and these are symptomatic therapies that do not stop progressive neurodegeneration; instead, they change the disease’s trajectory by stabilizing or delaying it and hence are unsuccessful in treating it [5].”
BackgroundHippocampus in health and disease: An overview
Dhikav, V., & Anand, K. (2012) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.104323 · Cited by 596 · cited 1×
“Damage appears to occur initially in the hippocampus and entorhinal cortex, parts of the brain that are essential in forming memories [2].”
BackgroundPinto, T. C. C., Machado, L., Bulgacov, T. M., Rodrigues-Júnior, A. L., Costa, M. L. G., Ximenes, R. C. C., & Sougey, E. B. (2019) · International Psychogeriatrics · doi:10.1017/s1041610218001370 · Cited by 596 · cited 1×
“Montreal Cognitive Assessment (MoCA) [23].”
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579 · cited 1×
“When these peptides aggregate, they can form amyloid plaques, a hallmark of AD and a neurotoxic component of the disease [83].”
BackgroundTimely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges
Dubois, B., Padovani, A., Scheltens, P., Rossi, A., & Dell’Agnello, G. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150692 · Cited by 562 · cited 1×
“Because AD symptoms can be mild and comparable to other disorders, making a diagnosis in the early stages can be challenging [147].”
BackgroundAlzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · cited 1×
“These vaccines are made to increase the development of anti-Aβ antibodies, which may aid in removing Aβ from the brain and preventing the buildup of Aβ plaques [79].”
BackgroundCannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
The importance of tau phosphorylation for neurodegenerative diseases
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475 · cited 1×
“Abnormal tau phosphorylation is a characteristic of several neurological conditions, including Alzheimer’s disease, frontotemporal dementia, and chronic traumatic encephalopathy [87].”
BackgroundThe Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
Proteolytic processing of Alzheimer’s β‐amyloid precursor protein
Zhang, H., Ma, Q., Zhang, Y., & Xu, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07519.x · Cited by 343 · cited 4×
“That is why it is necessary to develop new therapeutic aids with different structures and mechanisms of action, studying in the same time side effects and toxicity [109].”
BackgroundInfluentialMushtaq, G., Greig, N., Khan, J., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023141545 · Cited by 331 · cited 1×
“Predominantly present at the periphery, butyrylcholinesterase (BuChE), also hydrolyses ACh [15].”
BackgroundParsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 331 · cited 2×
“Combining memantine with cholinesterase inhibitors, which function on distinct neurotransmitter systems, would have various advantages [72].”
BackgroundAcetylcholinesterase inhibitors in Alzheimer’s disease
McGleenon, Dynan, & Passmore (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00026.x · Cited by 317 · cited 1×
“Inhibiting AChE leads to the activation of the parasympathetic nervous system (PSNS), which causes the most common side effects of this class of medication: bradycardia, syncope, and gastrointestinal issues such as nausea, vomiting, and diarrhea [25,26].”
BackgroundGill, S. S., Anderson, G. M., Fischer, H. D., Bell, C. M., Li, P., Normand, S.-L. T., & Rochon, P. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.43 · Cited by 306 · cited 1×
“Inhibiting AChE leads to the activation of the parasympathetic nervous system (PSNS), which causes the most common side effects of this class of medication: bradycardia, syncope, and gastrointestinal issues such as nausea, vomiting, and diarrhea [25,26].”
BackgroundMemantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Matsunaga, S., Kishi, T., & Iwata, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123289 · Cited by 284 · cited 2×
“In people with moderate–severe AD who do not tolerate AChE inhibitors, memantine monotherapy may be used as an alternative treatment [74].”
BackgroundThe Role of Cdk5 in Alzheimer’s Disease
Liu, S.-L., Wang, C., Jiang, T., Tan, L., Xing, A., & Yu, J.-T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9369-x · Cited by 269 · cited 1×
“CDK5 is most abundant in the brain and has a primary role in the development and function of neurons [88].”
BackgroundBores, G. M., Huger, F. P., Petko, W., Mutlib, A. E., Camacho, F., Rush, D. K., Selk, D. E., Wolf, V, Kosley, R. W., Davis, L., et al. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12928-5 · Cited by 248
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Al Balushi, K., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 247 · cited 1×
“Aducanumab, gantenerumab, solanezumab, and lecanemab are some of the compounds in phase III clinical studies [119,120].”
BackgroundRivastigmine for Alzheimer's disease
Birks, J. S., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub3 · Cited by 247 · cited 1×
“These side effects can be reduced by taking medicine in two doses at the same time as food [52].”
BackgroundMemantine for the Treatment of Dementia: A Review on its Current and Future Applications
Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., Garcia, M. L., Olloquequi, J., Casadesús, G., Beas-Zarate, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170672 · Cited by 245 · cited 1×
“To obtain better outcomes in treatment, it is used with cholinesterase inhibitors [66].”
MethodResearch and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor
Sugimoto, H., Ogura, H., Arai, Y., Iimura, Y., & Yamanishi, Y. (2002) · Japanese Journal of Pharmacology · doi:10.1254/jjp.89.7 · Cited by 240
Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240 · cited 1×
“Another potential target for these drugs could be the pathways involved in AD-related inflammation [96,97].”
BackgroundCannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
Aso, E., & Ferrer, I. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00037 · Cited by 237
Musicoterapia en la enfermedad de Alzheimer: efectos cognitivos, psicológicos y conductuales
Gallego, M. G., & García, J. G. (2016) · Neurología · doi:10.1016/j.nrl.2015.12.003 · Cited by 233
Music Therapy in the Treatment of Dementia: A Systematic Review and Meta-Analysis
Moreno-Morales, C., Calero, R., Moreno-Morales, P., & Pintado, C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00160 · Cited by 229
Ritchie, C., Smailagic, N., Noel-Storr, A. H., Ukoumunne, O., Ladds, E. C., & Martin, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010803.pub2 · Cited by 208 · cited 1×
“While many factors, such as genetics and lifestyle, influence a person’s chance of developing AD, age is by far the most significant; the disease is rare before the age of 65, and the recurrence rises in later decades, with a 24–33% chance of developing the disease by the age of 85 [4].”
BackgroundSelective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
Thomsen, T., & Kewitz, H. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90429-u · Cited by 207
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
Cognitive Impairment: Dementia and Alzheimer's Disease
Larson, E. B., Kukull, W. A., & Katzman, R. L. (1992) · Annual Review of Public Health · doi:10.1146/annurev.pu.13.050192.002243 · Cited by 192 · cited 2×
“They act by reversibly binding and inhibiting AChE, increasing acetylcholine levels [12].”
BackgroundMusic therapy and Alzheimer's disease: Cognitive, psychological, and behavioural effects
Gómez Gallego, M., & Gómez García, J. (2017) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.12.001 · Cited by 188
Behl, T., Kaur, G., Sehgal, A., Bhardwaj, S., Singh, S., Buhas, C., Judea-Pusta, C., Uivarosan, D., Munteanu, M. A., & Bungau, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031413 · Cited by 186 · cited 1×
“Inflammation has now been observed in numerous investigations using postmortem tissues from samples of AD patients, but the role of inflammation in AD is not yet fully understood [91,92].”
BackgroundSelf-citationEffects of medicinal plants on Alzheimer's disease and memory deficits
Akram, M., & Nawaz, A. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.205108 · Cited by 176
Massage and touch for dementia
Hansen, N. V., Jørgensen, T., & Ørtenblad, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004989.pub2 · Cited by 173
Music Intervention Approaches for Alzheimer’s Disease: A Review of the Literature
Leggieri, M., Thaut, M. H., Fornazzari, L., Schweizer, T. A., Barfett, J., Munoz, D. G., & Fischer, C. E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00132 · Cited by 165 · cited 1×
“It can foster a sense of connection, communication, relaxation, and emotional well-being [141,151].”
BackgroundDonepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics
Cacabelos, R. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a908 · Cited by 164 · cited 1×
“The administration of doses ≥ 10 mg leads to side effects, present in up to 70% of patients, such as muscle cramps, headache, dizziness, and gastrointestinal side effects such as vomiting and diarrhea [39].”
BackgroundRivastigmine in the treatment of Alzheimer's disease: an update
Onor, M. L., Trevisiol, M., & Aguglia, E. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.17 · Cited by 161 · cited 1×
“By inhibiting both AChE and BuChE that degrades acetylcholine in the human brain, the effect will be stronger, and the benefits of treatment greater, with higher synaptic neurotransmitter levels and improved cholinergic receptor function [46].”
BackgroundSultan, F., & Bower, J. M. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980413)393:3<353::aid-cne7>3.0.co;2-0 · Cited by 161
Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151 · cited 1×
“Confusion, hallucinations, and insomnia may also occur [77].”
BackgroundBehl, T., Makkar, R., Sehgal, A., Singh, S., Sharma, N., Zengin, G., BUNGAU, S. G., Andronie-Cioară, F. L., Munteanu, M. A., Brisc, M. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147432 · Cited by 147 · cited 1×
“Polyunsaturated fatty acids, which make up the membrane of neurons, are similarly vulnerable to reactive oxygen species [132].”
BackgroundSelf-citationGeerts, H., Guillaumat, P.-O., Grantham, C., Bode, W., Anciaux, K., & Sachak, S. (2005) · Brain Research · doi:10.1016/j.brainres.2004.11.042 · Cited by 146 · cited 1×
“The elimination of galantamine from the brain is faster than donepezil [38].”
BackgroundThe safety and tolerability of donepezil in patients with Alzheimer's disease
Jackson, S., Ham, R. J., & Wilkinson, D. G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.01848.x · Cited by 146 · cited 1×
“Patients with asthma or other lung diseases should be closely monitored, as cholinergic activation may lead to bronchoconstriction [42].”
BackgroundZhou, Y., Wang, S., & Zhang, Y. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp104258d · Cited by 142 · cited 3×
“The residues that form the catalytic triad are Ser203, His447, and Glu334 [16].”
BackgroundInfluentialHey, J. A., Yu, Y., Versavel, M., Abushakra, S. R., Kočiš, P., Power, A., Kaplan, P. L., Amedio, J. C., & Tolar, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0608-3 · Cited by 141 · cited 1×
“These were improved by coadministration with food or 1 week after starting the medicine [126,127].”
BackgroundClinical Pharmacokinetics of Galantamine
Farlow, M. R. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00005 · Cited by 134 · cited 1×
“The action on nicotinic receptors modulates the release of glutamate, serotonin, and gamma-aminobutyric acid with beneficial effects in relieving the symptoms of dementia, this being an advantage over substances that act only on cholinesterase [61,62].”
BackgroundUpdate on the use of memantine in Alzheimer’s disease
van Marum, R. J. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4048 · Cited by 127
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126 · cited 2×
“then switch to memantine after the illness has progressed to a moderate state while continuing to take the cholinesterase inhibitor [73].”
BackgroundUddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 124 · cited 1×
“The complexity of AD cannot therefore be fully explained by the amyloid cascade hypothesis [85].”
BackgroundSelf-citationClinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy
Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020) · International Journal of Alzheimer s Disease · doi:10.1155/2020/5380346 · Cited by 123 · cited 4×
“In this phase, drugs that do not meet certain requirements are eliminated to move on to the study of phase I requirements, thus saving time and money [99].”
BackgroundInfluentialPotential and Limits of Cannabinoids in Alzheimer’s Disease Therapy
Abate, G., Uberti, D. L., & Tambaro, S. (2021) · Biology · doi:10.3390/biology10060542 · Cited by 123 · cited 3×
“Cannabinoids, notably delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have been linked in certain studies to the possibility of treating AD [134,135].”
BackgroundMemantine agonist action at dopamine D2High receptors
Seeman, P. M., Caruso, C. M., & Lasaga, M. (2007) · Synapse · doi:10.1002/syn.20472 · Cited by 121 · cited 1×
“Improved dopamine transmission– memantine is a dopamine agonist that stimulates dopamine receptors, increasing dopaminergic function [70].”
BackgroundWesnes, K. A., Aarsland, D., Ballard, C. G., & Londos, E. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4109 · Cited by 110 · cited 1×
“Cognitively, memantine primarily increases attention and episodic memory (overall memory will be improved if attention is improved) [71].”
BackgroundActive immunotherapy options for Alzheimer’s disease
Winblad, B. G., Graf, A., Riviere, M., Andreasen, N., & Ryan, J. M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt237 · Cited by 110 · cited 1×
“It consists of a synthetic peptide antigen, corresponding to tau human protein sequence from 393 to 408 (a molecule capable of inducing an immune response) autoimmune responses of B cells or T cells against physiological forms [112,113].”
BackgroundAdvances and considerations in AD tau-targeted immunotherapy
Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 110 · cited 1×
“Therefore, utilizing drugs that simultaneously target both of these proteins may be more beneficial than a single therapy that only targets one [89,90].”
BackgroundGalantamine for Alzheimer's disease
Prvulovic, D., Hampel, H., & Pantel, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003592137 · Cited by 109 · cited 2×
“Galantamine had more side effects than donepezil but less than rivastigmine, according to research evaluating the adverse effects of several acetylcholinesterase inhibitors used to treat AD [64].”
BackgroundEfficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease
Schubert, D. A., Kepchia, D., Liang, Z., Dargusch, R., Goldberg, J., & Maher, P. A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1637-8 · Cited by 104
The Evolution of Tau Phosphorylation and Interactions
Trushina, N. I., Bakota, L., Mulkidjanian, A. Y., & Brandt, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00256 · Cited by 103 · cited 1×
“Neuronal microtubules are structural components that support the form of the cell and aid in the transportation of substances inside the cell [86].”
BackgroundJia, Q., Deng, Y., & Qing, H. (2014) · BioMed Research International · doi:10.1155/2014/837157 · Cited by 96 · cited 3×
“However, because some participants developed meningoencephalitis, it was discontinued because of cytotoxic T cells or the autoim une response [107,108].”
BackgroundInfluentialSkin tolerability associated with transdermal drug delivery systems: an overview
Ale, I. S., Lachapelle, J., & Maïbach, H. I. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0075-9 · Cited by 92
Alleviation of Drugs and Chemicals Toxicity: Biomedical Value of Antioxidants
Abdel‐Daim, M. M., Abo‐EL‐Sooud, K., Aleya, L., BUNGAU, S. G., Najda, A., & Saluja, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6276438 · Cited by 92
Self-citationGiacobini, E., Zhu, X., Williams, E., & Sherman, K. (1996) · Neuropharmacology · doi:10.1016/0028-3908(95)00157-3 · Cited by 91
Ohnishi, A., Mihara, M., Kamakura, H., Tomono, Y., Hasegawa, J., YAMAZAKI, K., Morishita, N., & Tanaka, T. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb01945.x · Cited by 86 · cited 1×
“This compound is slowly absorbed from the gastrointestinal tract and has an elimination half-life of 50–70 h in young volunteers (>100 h in elderly subjects) [36].”
BackgroundNOCHI, S., ASAKAWA, N., & Sato, T. (1995) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.18.1145 · Cited by 85
Animal-assisted therapy for dementia
Lai, N. M., Chang, S. M. W., Ng, S. S., Tan, S. L., Chaiyakunapruk, N., & Stanaway, F. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013243.pub2 · Cited by 84
Hey, J. A., Kočiš, P., Hort, J., Abushakra, S. R., Power, A., Vyhnálek, M., Yu, Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 81 · cited 1×
“These were improved by coadministration with food or 1 week after starting the medicine [126,127].”
BackgroundFarlow, M. R., Grossberg, G. T., Sadowsky, C., Meng, X., & Somogyi, M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12158 · Cited by 79
Computational Studies on Acetylcholinesterases
Xu, Y., Cheng, S., Sussman, J. L., Silman, I., & Jiang, H. (2017) · Molecules · doi:10.3390/molecules22081324 · Cited by 78
Ambure, P. S., Kar, S., & Roy, K. (2013) · Biosystems · doi:10.1016/j.biosystems.2013.12.002 · Cited by 76 · cited 1×
“The preponderance of ligands is located near the bottom of the hydrophobic pocket, with larger ligands such as donepezil reaching all the way to the aperture [21].”
BackgroundDifferent Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients
Nordberg, A., Darreh-Shori, T., Peskind, E., Soininen, H., Mousavi, M., Eagle, G., & Lane, R. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313961 · Cited by 76
Pharmacokinetic rationale for the rivastigmine patch
Cummings, J. L., Lefèvre, G. Y., Small, G. W., & Appel‐Dingemanse, S. (2007) · Neurology · doi:10.1212/01.wnl.0000281846.40390.50 · Cited by 72
Donepezil Inhibits Acetylcholinesterase via Multiple Binding Modes at Room Temperature
Silva, M. A., Kiametis, A. S., & Treptow, W. L. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01073 · Cited by 71
Trehalose against Alzheimer's Disease: Insights into a Potential Therapy
Khalifeh, M., Read, M. I., Barreto, G. E., & Sahebkar, A. (2020) · BioEssays · doi:10.1002/bies.201900195 · Cited by 68 · cited 1×
“Autophagy induction is achieved with the help of lysosomes, protecting neurons by cleaning protein aggregates [105,106].”
BackgroundHas Molecular Docking Ever Brought us a Medicine?
Phillips, M. A., Stewart, M. A., Woodling, D. L., & Xie, Z. (2018) · InTech eBooks · doi:10.5772/intechopen.72898 · Cited by 65
Behl, T., Kaur, I., Frățilă, O., Brata, R. D., & BUNGAU, S. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207443 · Cited by 52 · cited 1×
“Neuroinflammation is linked to the unusual production of proinflammatory cytokines, which activate signaling pathways, exacerbating the AD symptoms [94].”
BackgroundSelf-citationPresynaptic NMDA receptors and spike timing-dependent long-term depression at cortical synapses
Rodriguez-Moreno (2010) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2010.00018 · Cited by 51
Doody, R. S., Corey‐Bloom, J., Zhang, R., Li, H., Ieni, J. R., & Schindler, R. J. (2008) · Drugs & Aging · doi:10.2165/00002512-200825020-00008 · Cited by 50 · cited 1×
“The initial dose is 5 mg, and after 4 weeks, it can be increased to 10 mg [43].”
BackgroundLefèvre, G. Y., Pommier, F., Sedek, G., Allison, M. J., Huang, H. A., Kiese, B., Ho, Y., & Appel‐Dingemanse, S. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312154 · Cited by 45
Seniya, C., Khan, G. J., & Uchadia, K. (2014) · Biochemistry Research International · doi:10.1155/2014/705451 · Cited by 45 · cited 9×
“The enzymatic activity of AChE is decreased due to a steric hindrance and caused by the ligand bound to PAS [22].”
BackgroundInfluentialProspective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
Akter, R., Rahman, H., Behl, T., Chowdhury, M. A. R., Manirujjaman, M., Bulbul, I. J., Elshenawy, S. E., Ţiţ, D. M., & BUNGAU, S. G. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210218084444 · Cited by 44
Self-citationReview of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders
Desai, A. K., & Grossberg, G. T. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.4.653 · Cited by 41 · cited 1×
“To determine the beneficial effects of rivastigmine, it underwent extensive preclinical study, and the results showed that rivastigmine improved memory in the short term [44].”
ResultPiotrovsky, V., Peer, A. V., Osselaer, N. V., Armstrong, M., & Aerssens, J. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003251853 · Cited by 40 · cited 1×
“The action on nicotinic receptors modulates the release of glutamate, serotonin, and gamma-aminobutyric acid with beneficial effects in relieving the symptoms of dementia, this being an advantage over substances that act only on cholinesterase [61,62].”
BackgroundAducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 40 · cited 1×
“Aducanumab, gantenerumab, solanezumab, and lecanemab are some of the compounds in phase III clinical studies [119,120].”
BackgroundScharre, D. W., Chang, S. I., Nagaraja, H. N., Wheeler, N. C., & Kataki, M. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00930-4 · Cited by 38
Sadowsky, C., Micca, J. L., Grossberg, G. T., & Velting, D. M. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14r01654 · Cited by 37
Jhee, S. S., Shiovitz, T. M., Hartman, R. D., Messina, J. C., Anand, R., Sramek, J. J., & Cutler, N. R. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200203000-00013 · Cited by 37 · cited 1×
“Rivastigmine causes nausea and vomiting by directly stimulating the muscarinic receptors [53].”
BackgroundCombination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force
Gauthier, S., Alam, J., Fillit, H., Iwatsubo, T., Liu-Seifert, H., Sabbagh, M., Salloway, S., Sampaio, C., Sims, J. R., Sperling, B., et al. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.12 · Cited by 37
Chapter 1. Alzheimer's is a Multifactorial Disease
Samanta, S., Ramesh, M., & Govindaraju, T. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162732-00001 · Cited by 37
Multifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies
Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03415-w · Cited by 35 · cited 1×
“There has been a substantial research effort to construct multi-target-directed ligands (MTDLs) for the treatment of AD, a strategy based on the understanding that AD is a composite and multidimensional illness related to numerous independent but interwoven biological pathways [95].”
BackgroundSelf-citationMolecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 34 · cited 1×
“As a result, AD symptoms might gradually reduce, improving therapy results and patient adherence [98].”
BackgroundHeydorn, W. E. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.10.1527 · Cited by 32 · cited 1×
“After extensive liver metabolism, the parent compound is 93% bound to plasma proteins [37].”
BackgroundComputational Modeling of Drugs Against Alzheimer’s Disease
(2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7 · Cited by 32
Svobodová, B., Mezeiová, E., Hepnarová, V., Hrabinová, M., Múčková, Ľ., Kobrlová, T., Jun, D., Soukup, O., Jimeno, M. L., Marco, J. L., et al. (2019) · Biomolecules · doi:10.3390/biom9080379 · Cited by 32
Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimerʼs Disease
Aronson, S. M., van Baelen, B., Kavanagh, S., & Schwalen, S. (2009) · Drugs & Aging · doi:10.2165/00002512-200926030-00004 · Cited by 31 · cited 1×
“The daily optimal dosage varies from 16 to 24 mg, with favorable effects [65].”
BackgroundAcetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020
Galli, A., Mori, F., Benini, L., & Cacciarelli, N. (1994) · European Journal of Pharmacology Environmental Toxicology and Pharmacology · doi:10.1016/0926-6917(94)90062-0 · Cited by 31 · cited 1×
“Donepezil is an acetylcholinesterase inhibitor, which acts selectively and reversibly, decomposing acetylcholine [30].”
BackgroundDonepezil-associated Bradyarrhythmia in a Patient With Dementia With Lewy Bodies (DLB)
Rosenbloom, M. H., Finley, R., Scheinman, M. M., Feldman, M. D., Miller, B. L., & Rabinovici, G. D. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181b7642b · Cited by 26 · cited 1×
“Donepezil has vagotonic effects and increases the risk of bradycardia and heart block in both patients without heart problems and those with problems [40].”
BackgroundSkin tolerability of transdermal patches
Wohlrab, J., Kreft, B., & Tamke, B. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.574689 · Cited by 25
Albträume bei Patienten mit Alzheimer-Demenz durch Donepezil
Singer, M., Romero, B., Koenig, E., Förstl, H., & Brünner, H. (2005) · Der Nervenarzt · doi:10.1007/s00115-004-1856-7 · Cited by 23 · cited 1×
“Vivid dreams occurring during rapid eye movement (REM) sleep are one of the most common side effects [28].”
BackgroundMusic Therapy and Neuroscience: Opportunities and Challenges
O'Kelly, J. W. (2016) · Voices A World Forum for Music Therapy · doi:10.15845/voices.v16i2.872 · Cited by 23
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
Akter, R. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/19963181mte0pmzel3 · Cited by 20
Rosenzweig, A. B., & Sittambalam, C. D. (2015) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v5.27950 · Cited by 14 · cited 1×
“Originally used to sedate intubated and mechanically ventilated patients in intensive care, it is administered sublingually in agitation associated with dementia [101,102].”
MethodAgboton, C., Mahdavian, S., Singh, A., Ghazvini, P., Hill, A. M., & Sweet, R. (2014) · Mental Health Clinician · doi:10.9740/mhc.n222761 · Cited by 14 · cited 1×
“Taking donepezil in the morning can reduce nightmares caused by the stimulation of the visual cortex [41].”
BackgroundBenito‐Cuesta, I., Ordóñez‐Gutiérrez, L., & Wandosell, F. G. (2021) · Metabolites · doi:10.3390/metabo11070421 · Cited by 14 · cited 1×
“Autophagy induction is achieved with the help of lysosomes, protecting neurons by cleaning protein aggregates [105,106].”
BackgroundDoytchinova, I. A., Atanasova, M., Stavrakov, G., Philipova, I., & Zheleva‐Dimitrova, D. (2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7_6 · Cited by 7
Alzheimer's Disease (Oxford Neurology Library)
Allen, S. J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198779803.001.0001 · Cited by 7
Practical Pharmacology for Alzheimer’s Disease
Kudo, T., Davis, K. L., Blesa, R., & Wilkinson, D. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-26206-2 · Cited by 6 · cited 1×
“Constipation, gastritis, and urine incontinence are all substantially more frequent [54].”
BackgroundSilverman, M., Wallner, B., Key, C., Duggan, S., & Reynolds, L. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.041144 · Cited by 2
Research works printed but not linked: 3
- Wolfe, M.S. (2018). The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms, Academic Press.
- BIOVIA, 2017, BIOVIA Discovery Studio Visualizer, Softw. Version, 20, 779
- Darvesh, 1998, Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation, J. Comp. Neurol., 393, 374, 10.1002/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“51 These drugs primarily function by modulating neurotransmitter levels but cannot alter the course of the disease, 409,411 which are instructive for designing new drugs.”
BackgroundRamakrishna, K., Nalla, L. V., Naresh, D., Venkateswarlu, K., Viswanadh, M. K., Nalluri, B. N., Chakravarthy, G., Duguluri, S., Singh, P., Rai, S. N., et al. (2023) · Diseases · doi:10.3390/diseases11030089 · Cited by 192
Baran, M. F., Keskin, C., Baran, A., Hatipoğlu, A., Yıldıztekin, M., Küçükaydın, S., Kurt, K., Hoşgören, H., Sarker, M. M. R., Sufianov, A. A., et al. (2023) · Molecules · doi:10.3390/molecules28052310 · Cited by 159
Diet and lifestyle impact the development and progression of Alzheimer’s dementia
Arora, S., Santiago, J. A., Bernstein, M., & Potashkin, J. A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1213223 · Cited by 113
Song, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114647 · Cited by 97
Metadata
- Authors
- Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M.
- Affiliations
- University of Oradea (RO)
- University of Petroleum and Energy Studies (IN)
- Shanghai Jiao Tong University (CN)
- Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania
- Corresponding author
- Negru, Paul Andrei
- Bungau, Simona Gabriela
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-12-28
- Volume
- 12
- Issue
- 1
- Pages
- 131
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9818415
- OpenAlex
- W4313361457
- Cited by
- 96
- References
- 124
- Citations by year
- 2026: 25 · 2025: 26 · 2024: 28 · 2023: 17
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Romanian Ministry of Research, Innovation and Digitisation (29 PFE/30.12.2021)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, pharmacotherapy, cholinesterase inhibitors, glutamate receptor antagonists, disease-modifying therapy, dementia, molecular docking, drug development, cognitive impairment
- MeSH terms
- Aged, Alzheimer Disease, Cholinesterase Inhibitors, Humans, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.